首页|期刊导航|动物模型与实验医学（英文）|Studying host genetic background effects on multimorbidity of intestinal cancer development, type 2 diabetes and obesity in response to oral bacterial infection and high-fat diet using the collaborative cross (CC) lines
Studying host genetic background effects on multimorbidity of intestinal cancer development, type 2 diabetes and obesity in response to oral bacterial infection and high-fat diet using the collaborative cross (CC) lines
Asal Milhem Hanifa J.Abu Toamih- Atamni Luna Karkar Yael Houri- Haddad Fuad A.Iraqi
动物模型与实验医学（英文）2021，Vol.4Issue(1)：27-39,13.
动物模型与实验医学（英文）2021，Vol.4Issue(1)：27-39,13.DOI:10.1002/ame2.12151
Studying host genetic background effects on multimorbidity of intestinal cancer development, type 2 diabetes and obesity in response to oral bacterial infection and high-fat diet using the collaborative cross (CC) lines
Studying host genetic background effects on multimorbidity of intestinal cancer development, type 2 diabetes and obesity in response to oral bacterial infection and high-fat diet using the collaborative cross (CC) lines
摘要
关键词
high-fat diet (42％ fat)/intestinal cancer/multimorbidity/obesity/oral bacterial infection/type 2 diabetes (T2D)Key words
high-fat diet (42％ fat)/intestinal cancer/multimorbidity/obesity/oral bacterial infection/type 2 diabetes (T2D)引用本文复制引用
Asal Milhem,Hanifa J.Abu Toamih- Atamni,Luna Karkar,Yael Houri- Haddad,Fuad A.Iraqi..Studying host genetic background effects on multimorbidity of intestinal cancer development, type 2 diabetes and obesity in response to oral bacterial infection and high-fat diet using the collaborative cross (CC) lines[J].动物模型与实验医学（英文）,2021,4(1):27-39,13.基金项目
The present work is part of an MSc thesis by Asal Milhem. The au-thors declare no competing financial interests or other associations that may pose a conflict of interest (eg pharmaceutical stock owner-ship, consultancy). This report was supported by Binational Science Foundation (BSF) grant number 2015077, German Israeli Science Foundation (GIF) grant I- 63- 410.20- 2017, Israeli Science Foundation (ISF) grant 1085/18 and core fund form Tel- Aviv University. The au-thors thank Ms Yasmeen Iraqi for her comments and suggestions on the report. （eg pharmaceutical stock owner-ship, consultancy）
